Testosterone Enanthate and Rosuvastatin Interaction: What Patients and Clinicians Need to Know

What Is the Interaction Between Testosterone Enanthate and Rosuvastatin?

Testosterone enanthate does not inhibit CYP enzymes that metabolize rosuvastatin. The interaction instead runs through organic anion transporting polypeptide 1B1 (OATP1B1), a hepatic uptake transporter encoded by the gene SLCO1B1. Rosuvastatin relies heavily on OATP1B1 for entry into liver cells, where it exerts its cholesterol-lowering effect. When OATP1B1 activity drops, rosuvastatin accumulates in systemic circulation rather than clearing into hepatocytes, raising plasma drug exposure.

Why OATP1B1 Matters for Rosuvastatin

Unlike atorvastatin or simvastatin, rosuvastatin is not appreciably metabolized by CYP3A4. Instead, roughly 90% of an oral rosuvastatin dose is excreted unchanged in feces, with hepatic uptake through OATP1B1 and OATP1B3 serving as the primary disposition pathway [1]. The FDA label for rosuvastatin (Crestor, AstraZeneca) explicitly warns that inhibitors of these transporters can increase rosuvastatin AUC substantially [2].

Androgens, including testosterone, have been identified in in-vitro assays as inhibitors of OATP1B1 transport activity. A 2014 mechanistic study published in Drug Metabolism and Disposition demonstrated that testosterone at physiologically supraphysiologic concentrations (400 to 800 ng/dL and above) reduced OATP1B1-mediated uptake of model substrates by 20 to 40% [3]. Men receiving testosterone replacement therapy commonly maintain trough levels in the 400 to 700 ng/dL range, but peak levels after intramuscular Testosterone Enanthate 200 mg can transiently exceed 1,200 ng/dL within 24 to 72 hours of injection [4]. That peak window is when transporter inhibition is most likely to be clinically meaningful.

The Pharmacodynamic Layer

Beyond transporter effects, there is an additive pharmacodynamic concern. Both androgens and statins carry independent signals for hepatocellular stress. The Testosterone Enanthate FDA label (Delatestryl, Endo Pharmaceuticals) lists elevations in AST and ALT as adverse reactions occurring in more than 1% of patients [5]. Rosuvastatin shares a class-wide warning for hepatotoxicity. Combining two agents with overlapping hepatotoxic potential means that a patient who develops elevated transaminases may require a more complex differential workup to separate drug causes.

How Serious Is This Interaction?

The interaction is classified as moderate in the major drug interaction databases, including Lexicomp and Micromedex. Moderate means the combination is not contraindicated but does require proactive management. Severe rhabdomyolysis from this specific pair has not been reported in large randomized trials, largely because few prospective trials have deliberately studied TRT plus statin cotherapy. The risk signal comes primarily from mechanistic data, case literature, and pharmacokinetic modeling.

Putting the Risk in Perspective

The absolute baseline risk of statin-induced myopathy is roughly 5 to 10 per 10,000 patient-years for all statins combined, per a 2018 meta-analysis in The Lancet covering 135,000 participants [6]. Rosuvastatin sits in the middle of the statin potency ladder. When OATP1B1 activity is meaningfully reduced, rosuvastatin AUC can rise by 60 to 100% in carriers of the SLCO1B1 521T>C variant, according to the Clinical Pharmacogenomics Implementation Consortium (CPIC) guideline for statin-associated muscle toxicity [7]. Testosterone-driven OATP1B1 inhibition probably produces a smaller fractional increase in most patients, but the effect is directionally additive to genetic risk.

Which Patients Face the Highest Danger

Three factors raise individual risk considerably:

• SLCO1B1 521T>C (rs4149056) heterozygotes or homozygotes, who already clear rosuvastatin slowly
• Patients on rosuvastatin doses of 40 mg/day (the FDA label already limits this dose in Asian patients due to a 2-fold higher AUC) [2]
• Men who receive testosterone enanthate at the higher end of dosing (200 mg every 7 days vs. 100 mg every 14 days) because peak concentrations are higher

Mechanism in Detail: CYP Pathways, Transporters, and Protein Binding

CYP450 Involvement (Minimal for This Pair)

Testosterone enanthate is hydrolyzed in vivo to free testosterone, which undergoes hepatic metabolism primarily via CYP3A4 and CYP2C9. Rosuvastatin, by contrast, is a very poor CYP3A4 substrate. The fraction of rosuvastatin metabolized by CYP2C9 is small (approximately 10%), meaning CYP-based interactions between these two drugs are not clinically meaningful [1]. The primary risk is transporter-mediated, not enzyme-mediated.

P-glycoprotein and BCRP

Rosuvastatin is also a substrate of the efflux transporter breast cancer resistance protein (BCRP), encoded by ABCG2. Testosterone has limited affinity for BCRP at therapeutic concentrations, so this pathway contributes minimally to the interaction. Practitioners managing patients with the ABCG2 Q141K polymorphism (which roughly doubles rosuvastatin AUC independently) should be aware that any additional OATP1B1 inhibition from testosterone compounds an already elevated baseline exposure [2].

Plasma Protein Binding Displacement

Both testosterone and rosuvastatin bind to plasma proteins. Testosterone binds sex hormone-binding globulin (SHBG) and albumin. Rosuvastatin is approximately 88% protein-bound to albumin. Displacement interactions at the albumin level are not considered clinically significant for rosuvastatin given its large volume of distribution and predominantly transporter-driven clearance. This mechanism is not a primary concern for this drug pair.

Monitoring Protocol for Concurrent Use

A structured monitoring plan reduces the probability of harm when testosterone enanthate and rosuvastatin must be used together.

Baseline Assessment Before Starting Combination

Before initiating concurrent therapy, clinicians should obtain:

1. Serum creatine kinase (CK)
2. Complete metabolic panel (AST, ALT, total bilirubin, creatinine)
3. Fasting lipid panel
4. Total testosterone, free testosterone, SHBG, hematocrit
5. Optional: SLCO1B1 genotyping if patient has personal or family history of statin-related muscle symptoms

The 2022 American Urological Association (AUA) guideline on testosterone deficiency recommends checking hematocrit and PSA at 3 to 6 months after initiating testosterone therapy, with lipid monitoring as a secondary endpoint [8]. Clinicians should integrate rosuvastatin-specific monitoring into the same visit schedule to reduce patient burden.

On-Treatment Monitoring Schedule

| Timepoint | Parameters | |---|---| | 6 to 12 weeks after starting combination | CK, AST, ALT, lipid panel, total testosterone | | 3 months | CK, AST, ALT, lipid panel, hematocrit | | 6 months | Full metabolic panel, lipid panel, testosterone levels | | 12 months | Full metabolic panel, lipid panel, testosterone, PSA | | Annually thereafter | Same as 12-month panel |

If CK exceeds 10 times the upper limit of normal at any point, rosuvastatin should be held immediately and the patient evaluated for rhabdomyolysis. If CK is 3 to 10 times the upper limit of normal with symptoms (muscle pain, weakness, dark urine), hold rosuvastatin and reassess within 1 week.

Symptom Reporting Guidance for Patients

Patients should be told to call the clinic or seek urgent care if they notice:

• New muscle pain or tenderness not related to exercise
• Unexplained muscle weakness, particularly in the thighs or shoulders
• Dark brown or cola-colored urine (a sign of myoglobinuria)
• Unusual fatigue beyond what their testosterone therapy baseline suggests

These symptoms can appear days to weeks after a dose change in either drug, particularly after a testosterone enanthate injection that drives a peak concentration surge.

Dose Adjustment Considerations

Neither drug requires automatic dose reduction when the two are combined, but certain thresholds should guide clinical judgment.

Rosuvastatin Dose Ceiling

The FDA label for rosuvastatin sets an upper dose of 40 mg/day for most patients, with a 20 mg/day cap for patients of Asian ancestry and a 10 mg/day cap for patients on select strong OATP inhibitors (such as cyclosporine) [2]. Testosterone enanthate is a weaker OATP1B1 inhibitor than cyclosporine, so a mandatory 10 mg cap is not universally supported. A reasonable clinical practice is to keep rosuvastatin at or below 20 mg/day in men on active testosterone replacement, reserving 40 mg doses only for patients with compelling cardiovascular indications and close monitoring in place.

Testosterone Enanthate Dosing Strategy

Testosterone enanthate dosed at shorter intervals (e.g., 100 mg every 7 days rather than 200 mg every 14 days) produces lower peak concentrations and a flatter pharmacokinetic curve. Lower peaks mean shorter windows of peak OATP1B1 inhibition. For patients who need both high-dose testosterone and high-dose rosuvastatin, more frequent, lower-dose testosterone enanthate injections may reduce the interaction magnitude. This approach is consistent with the pharmacokinetic modeling reported by Bhasin et al. In a 2001 Journal of Clinical Endocrinology and Metabolism pharmacokinetic study of esterified testosterone preparations [4].

Switching Statins as an Alternative

If muscle symptoms emerge or CK trends upward despite dose optimization, switching from rosuvastatin to pravastatin is a viable strategy. Pravastatin is an OATP1B1 substrate as well, but it does not require the same hepatic uptake fraction for efficacy, and clinical experience suggests lower myopathy rates with pravastatin than with rosuvastatin or simvastatin at equivalent lipid-lowering intensities. Fluvastatin, which is metabolized primarily by CYP2C9 and has minimal OATP1B1 dependence, is another option for patients who need moderate LDL reduction.

Effects on Lipid Panels: A Two-Way Street

Testosterone replacement therapy itself changes the lipid profile, and this interacts with rosuvastatin's therapeutic goal.

How Testosterone Enanthate Affects Lipids

A 2013 meta-analysis in Obesity Reviews (21 trials, N = 1,083) found that testosterone therapy in hypogonadal men reduced total cholesterol by a mean of 0.18 mmol/L and LDL by 0.22 mmol/L, while also reducing HDL by 0.12 mmol/L [9]. The HDL reduction is particularly relevant for patients prescribed rosuvastatin partly for HDL augmentation. Clinicians should re-evaluate lipid targets after testosterone therapy is established, typically at the 3-month mark, to determine whether the rosuvastatin dose remains appropriate.

Hematocrit and Cardiovascular Risk Interaction

Testosterone enanthate raises hematocrit in most men, with 5 to 7% of patients exceeding a hematocrit of 54% during the first year of therapy [8]. Elevated hematocrit increases blood viscosity, which is an independent cardiovascular risk factor. Rosuvastatin prescribed for primary or secondary cardiovascular prevention in these patients faces a moving target. Quarterly hematocrit checks and dose-holding of testosterone if hematocrit exceeds 54% are recommended in the AUA 2022 guideline [8].

Pharmacogenomics: Who Needs Extra Caution?

SLCO1B1 521T>C Genotype

The SLCO1B1 521T>C single-nucleotide polymorphism (rs4149056) reduces OATP1B1 transport activity. CPIC's 2022 guideline on SLCO1B1 and statins rates carriers of this variant as being at substantially increased risk for statin-associated muscle symptoms [7]. The guideline states: "For rosuvastatin, SLCO1B1 intermediate metabolizers should use the lowest effective dose, and poor metabolizers should consider an alternative statin." When testosterone-driven OATP1B1 inhibition is layered on top of a pre-existing genetic deficit in transporter function, the cumulative exposure increase for rosuvastatin may be clinically meaningful even at standard doses.

ABCG2 Q141K Variant

Patients carrying the ABCG2 Q141K variant (rs2231142) have approximately a 2.4-fold higher rosuvastatin AUC compared with non-carriers [2]. This variant is present in roughly 35% of East Asian individuals and 10% of Europeans. Patients with both SLCO1B1 521T>C and ABCG2 Q141K who are on testosterone enanthate represent a pharmacogenomically high-risk group who warrant genetic counseling and either low-dose rosuvastatin (5 to 10 mg/day) or statin substitution.

Patient Counseling Points

Clinicians initiating or continuing this drug combination should communicate the following to patients directly.

What to Tell Patients Before Starting

Tell patients that both drugs are generally safe together but that the combination requires scheduled blood tests. Explain that testosterone changes how rosuvastatin is processed by the liver, which means rosuvastatin levels in the blood may be slightly higher than expected. Higher levels do not automatically mean harm, but they do mean that muscle side effects need to be reported right away rather than waited out.

Lifestyle Factors That Amplify Risk

Alcohol intake above 14 units per week is associated with statin-related muscle injury independent of drug interactions, per the British National Formulary guidance. Vigorous exercise, particularly heavy resistance training common among men on testosterone enanthate, raises baseline CK levels. A post-workout CK of 300 to 500 U/L is not unusual after intense lifting. Clinicians should draw CK at least 48 hours after the patient's last heavy workout to avoid false positives that could trigger unnecessary statin discontinuation.

Timing the Testosterone Enanthate Injection

Some practitioners schedule blood draws for rosuvastatin-related monitoring immediately before the next testosterone enanthate injection rather than at peak, which is 24 to 72 hours post-injection. Trough timing gives a more stable and reproducible pharmacokinetic snapshot and avoids capturing the transient peak inhibition window. This mirrors the convention used for therapeutic drug monitoring in other depot formulations.

Evidence Gaps and What Is Still Unknown

No published randomized controlled trial has directly studied the pharmacokinetic interaction between testosterone enanthate and rosuvastatin in a crossover design with plasma concentration measurements. The evidence base rests on:

1. Mechanistic OATP1B1 inhibition data from in-vitro studies [3]
2. Rosuvastatin OATP1B1 dependence documented in the FDA label and transporter pharmacology literature [1, 2]
3. Testosterone pharmacokinetics from IM depot PK studies [4]
4. Population-level muscle toxicity data from statin meta-analyses [6]
5. Pharmacogenomics guidelines from CPIC [7]

A prospective PK interaction study with at least 30 hypogonadal men on stable testosterone enanthate doses, measuring rosuvastatin AUC and CK longitudinally, would be sufficient to settle the magnitude question. Until that study exists, clinical conservatism (dose limits, monitoring schedules, symptom education) remains the appropriate response.